Stabilitech’s AntiSpare technology enables a stable form of vaccine to be  significantly more immunogenic. In some studies, we have been able to demonstrate an antigen sparing effect of up to 100 fold in which one hundredth of the usual vaccine dose gives rise to an equivalent immune response as illustrated in the graph below.


Influenza multi-valent vaccine – whole inactivated influenza vaccine containing 16 current strains. Using AntiSpare, we aim to produce a vaccine that will provide life-long immunity for all influenza strains.


Low cost per dose – Dose-sparing of vaccines could be beneficial to immunization programmes, particularly in resource-poor settings, by potentially reducing the per-injection cost (including transport and storage) of vaccines because more doses could be obtained from the existing vaccine supply.

Increased supply – Dose-sparing might also “stretch” the availability of vaccines in cases where supply is limited by manufacturing capacity. Antigen sparing is regarded as crucial for pandemic vaccine development due in the large part to the fact that worldwide influenza vaccine production capacity is limited and where global production capacity limits access to a vaccine at the start of a pandemic. For example, in 2009, H1N1 vaccine was not available in most low-income countries until 8 months after WHO’s declaration of the influenza pandemic.

Demonstration of antigen sparing using Influenza vaccine